FDA Orders Unapproved Oxycodone Drugs Halted

Its notice in the Federal Register affects companies that manufacture and distribute unapproved single-ingredient, immediate-release oxycodone drug products in oral dosage forms, including tablets, capsules, and oral solutions.

The U.S. Food and Drug Administration has published a notice ordering companies to stop manufacturing and distributing some unapproved drugs that contain oxycodone. The agency said this step is part of its Unapproved Drugs Initiative to remove unapproved new drugs from the market.

The affected drugs -- single-ingredient, immediate-release oxycodone drug products in oral dosage forms, including tablets, capsules, and oral solutions -– haven't been evaluated by FDA for safety, effectiveness, manufacturing quality, or appropriate labeling. Oxycodone is listed under Schedule II of the Controlled Substances Act with an abuse liability similar to other opioid agonists.

The notice says FDA is aware of unapproved 5 mg capsules and unapproved oral solutions in 5 mg/5 mL and 20 mg/mL strengths. It also is aware of two adverse events cited in the notice: a 21-month-old patient prescribed oxycodone at a strength of 1 mg/mL but instead given one at 20 mg/mL who suffered respiratory failure but was successfully resuscitated, and an 18-year-old patient whose prescription was to take one 5 mg teaspoon every four hours but was given a 20 mg/mL solution. This second patient went into a coma with organ failure and was placed in intensive care, and at the time of the report to FDA "was able to speak but only with a limited vocabulary," according to the notice.

"It's a high public health priority for FDA to remove these unapproved products from the market to minimize consumer exposure to drugs that may be unsafe, ineffective, and of poor quality," said Ilisa Bernstein, acting director of the Office of Compliance in FDA's Center for Drug Evaluation and Research. "Since FDA-approved versions of these oral dosage forms are available by prescription, there should be no negative impact on consumers as a result of this action and no disruptions to the drug supply."

Companies are expected to stop making the products within 45 days and stop shipping them within 90 days. Affected products were introduced onto the market before Sept. 19, 2011, were listed in FDA's Drug Registration and Listing System before July 6, 2012, and were being commercially used or sold before July 6, 2012.

Download Center

  • Safety Metrics Guide

    Is your company leveraging its safety data and analytics to maintain a safe workplace? With so much data available, where do you start? This downloadable guide will give you insight on helpful key performance indicators (KPIs) you should track for your safety program.

  • Job Hazard Analysis Guide

    This guide includes details on how to conduct a thorough Job Hazard Analysis, and it's based directly on an OSHA publication for conducting JHAs. Learn how to identify potential hazards associated with each task of a job and set controls to mitigate hazard risks.

  • A Guide to Practicing “New Safety”

    Learn from safety professionals from around the world as they share their perspectives on various “new views” of safety, including Safety Differently, Safety-II, No Safety, Human and Organizational Performance (HOP), Resilience Engineering, and more in this helpful guide.

  • Lone Worker Safety Guide

    As organizations digitalize and remote operations become more commonplace, the number of lone workers is on the rise. These employees are at increased risk for unaddressed workplace accidents or emergencies. This guide was created to help employers better understand common lone worker risks and solutions for lone worker risk mitigation and incident prevention.

  • EHS Software Buyer's Guide

    Learn the keys to staying organized, staying sharp, and staying one step ahead on all things safety. This buyer’s guide is designed for you to use in your search for the safety management solution that best suits your company’s needs.

  • Vector Solutions

Featured Whitepaper

OH&S Digital Edition

  • OHS Magazine Digital Edition - July August 2022

    July / August 2022

    Featuring:

    • CONFINED SPACES
      Specific PPE is Needed for Entry and Exit
    • HAZARD COMMUNICATION
      Three Quick Steps to Better HazCom Training
    • GAS DETECTION
      Building a Chemical Emergency Toolkit
    • RESPIRATORY PROTECTION
      The Last Line of Defense
    View This Issue